Drug Trial Radar · NCT00946712
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: May 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,333
Actual
Start
Jul 15, 2009
Primary completion
Aug 31, 2017
Study completion Feb 8, 2022
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jul 27, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial studies carboplatin and paclitaxel to compare how well they work with or without bevacizumab and/or cetuximab in treating patients with stage IV or non-small cell lung cancer that has returned after a period of improvement (recurrent). Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may prevent the growth of new blood vessels that tumor needs to grow. Cetuximab may also stop cancer cells from growing by binding and interfering with a protein on the surface of the tumor cell that is needed for tumor growth. It is not yet known whether giving carboplatin and paclitaxel are more effective with or without bevacizumab and/or cetuximab in treating patients with non-small cell lung cancer.
Conditions
- Recurrent Large Cell Lung Carcinoma
- Recurrent Lung Adenocarcinoma
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Large Cell Lung Carcinoma
- Stage IV Lung Adenocarcinoma
- Stage IV Squamous Cell Lung Carcinoma
Interventions
BevacizumabBiological
Given IV
CarboplatinDrug
Given IV
CetuximabBiological
Given IV
Laboratory Biomarker AnalysisOther
Correlative studies
PaclitaxelDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) in the Entire Study PopulationTime frame: Patients will be followed every 3 weeks while on protocol treatment. Once off all protocol treatment, patients will be followed every 6 months until death or up to 3 years
- Progression-free Survival (PFS) of EGFR FISH-positive Patients by Institutional ReviewTime frame: Disease assessment will be repeated every 6 weeks for the first 9 months and every 3 months thereafter, until disease progression.
Locations
798 sites in 2 countries. Site status is shown where the registry gives one.
Northeast Alabama Regional Medical Center
Anniston, Alabama
Gulf Coast MBCCOP
Mobile, Alabama
Providence Hospital
Mobile, Alabama
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Regional Hospital
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Fairbanks Memorial Hospital
Fairbanks, Alaska
The University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona
The University of Arizona Cancer Center-North Campus
Tucson, Arizona
The University of Arizona Medical Center-University Campus
Tucson, Arizona
Fowler Family Center for Cancer Care
Jonesboro, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
East Bay Medical Oncology Hematology Medical Associates-Antioch
Antioch, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Mills - Peninsula Hospitals
Burlingame, California
East Bay Radiation Oncology Center
Castro Valley, California
Eden Hospital Medical Center
Castro Valley, California
Valley Medical Oncology Consultants-Castro Valley
Castro Valley, California
Enloe Medical Center
Chico, California
City of Hope Comprehensive Cancer Center
Duarte, California
Epic Care-Dublin
Dublin, California
Bay Area Breast Surgeons Inc
Emeryville, California
Epic Care Partners in Cancer Care
Emeryville, California
Northbay Cancer Center
Fairfield, California
Valley Medical Oncology Consultants-Fremont
Fremont, California
Marin General Hospital
Greenbrae, California
UC San Diego Moores Cancer Center
La Jolla, California
Loma Linda University Medical Center
Loma Linda, California
Los Angeles County-USC Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Contra Costa Regional Medical Center
Martinez, California
Fremont - Rideout Cancer Center
Marysville, California
Mather Veteran Affairs Medical Center
Mather, California
Mercy UC Davis Cancer Center
Merced, California
Memorial Medical Center
Modesto, California
El Camino Hospital
Mountain View, California
Sutter Cancer Research Consortium
Novato, California
Showing 40 of 798 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.